AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24150660
Drug: Ibuprofen alone
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen alone (24 mg·kg(‐1)·day(‐1))
Trial: 21341925
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (TN) 0-, 7-, 14-, or 21-mg doses
Trial: 21341925
Drug: Smoking (independent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoking (independent of TN dose)
Trial: 11188776
Drug: IVIG treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG treatment (immunoglobulin 10% 1 g/kg bodyweight)
Trial: 11188776
Drug: Placebo (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.1 g albumin/vial)
Trial: 9538657
Drug: 3 x
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 80 mg sotalol
Trial: 9538657
Drug: 2 x
RxNorm normalized name: anti-HER2 x HER2 ADC
DrugBank: Zanidatamab zovodotin (DB15472)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 160 mg sotalol
Trial: 9538657
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of sotalol
Trial: 26227494
Drug: Diaphragm biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diaphragm biofeedback training (DBT) + rabeprazole proton pump inhibitor (PPI)
Trial: 24745020
Drug: Preemptive thoracic
RxNorm normalized name: Thoracol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive thoracic epidural analgesia (TEA) administered as a bolus before surgical incision and continued until the end of surgery.
Trial: 22697440
Drug: Transdiagnostic cognitive-behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic cognitive-behavioral treatments (CBT) for anxiety disorders, 12-week duration
Trial: 18973896
Drug: Cyclic oral
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic oral contraceptive therapy (low-dose, monophasic OCP for 24 months)
Trial: 18973896
Drug: Continuous oral
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous oral contraceptive therapy (low-dose, monophasic OCP for 24 months)
Trial: 18973896
Drug: No therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No therapy (nonusers)
Trial: 18928120
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (oral nylestriol, 2 mg/time, twice a month for 3 months, with medroxyprogesterone from the third month)
Trial: 15970467
Drug: Psychiatric case
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychiatric case management (exact details of dosage and duration not available)
Trial: 12490113
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir at 300 mg/day for 1 year (prophylaxis group)
Trial: 9531028
Drug: Dalteparin, 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin, 120 IU/kg bw twice daily for 5-8 days and 7,500 IU once daily for 35-40 days
Trial: 9531028
Drug: Dalteparin, lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin, lower dose after initial high dose
Trial: 23736109
Drug: Antihypertensive medications
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive medications (average of 1.7 medications)
Trial: 12612295
Drug: Montelukast 10
RxNorm normalized name: montelukast 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast 10 mg + inhaled budesonide 800 microg/day
Trial: 12612295
Drug: Double dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double dose inhaled budesonide 1600 microg/day
Trial: 10832071
Drug: CoQ(10) supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CoQ(10) supplementation (50 mg three times daily)
Trial: 8194411
Drug: Manual injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual injection technique
Trial: 31209657
Drug: Venetoclax in
RxNorm normalized name: Product containing venetoclax in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax in combination with Rituximab
Trial: 25613938
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (IVB) at 0.625 mg per eye per dose
Trial: 25613938
Drug: Intravitreal injection
RxNorm normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of bevacizumab (IVB) at 0.25 mg per eye per dose
Trial: 21807052
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg dose of parvovirus B19 recombinant capsid
Trial: 21807052
Drug: 2.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 μg dose of recombinant capsid with MF59
Trial: 21807052
Drug: 25 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 μg dose of recombinant capsid with MF59
Trial: 15744699
Drug: Fondaparinux 2.5
RxNorm normalized name: FONDAPARINUX 2.5MG/0.5ML INJ SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fondaparinux 2.5 mg once-daily subcutaneous regimen starting postoperatively
Trial: 11120907
Drug: Erythromycin (1-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (1-100 microg/ml)
Trial: 3791269
Drug: Methylphenidate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10 mg with breakfast and 5 mg with lunch for 3 days)
Trial: 29442148
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg maintenance dose (MD)
Trial: 29442148
Drug: Routine clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine clinical dosage regimen (180 mg LD, 90 mg MD)
Trial: 25668998
Drug: Intravenous dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dexmedetomidine 0.5 μg/kg followed by epidural dexmedetomidine 0.5 μg/kg along with 5 ml; 0.25% ropivacaine
Trial: 25668998
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl 1 μg/kg followed by epidural fentanyl 1 μg/kg along with 5 ml; 0.25% ropivacaine
Trial: 24622263
Drug: daglutril (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daglutril (300 mg/day)
Trial: 16782685
Drug: Stuttering Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stuttering Treatment Research Evaluation and Assessment Tool (STREAT)
Trial: 8692115
Drug: High-dose cytosine-arabinoside/daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytosine-arabinoside/daunorubicin (HDAC)
Trial: 31369152
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (TIVA with propofol and remifentanil)
Trial: 25454683
Drug: Spinal manipulative
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal manipulative therapy (SMT) with home exercise
Trial: 24428802
Drug: Dietary behavior
RxNorm normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dietary behavior modification treatment (1.5 hours of individual counseling at study start, 1 hour at follow-up home visits after 6 weeks, support through cell phone text messages every two weeks, aimed to reduce dietary intake by 500 kcal/day)
Trial: 9166373
Drug: Emerging therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Emerging therapies for multiple sclerosis management, specific therapies not detailed, duration not specified.
Trial: 8319063
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g of a negative oral contrast agent (oral magnetic particles) administered in 800 ml of a viscous suspension
Trial: 31425479
Drug: Non-ipilimumab control
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Non-ipilimumab control treatments
Trial: 30277862
Drug: rilonacept (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rilonacept (320 mg loading dose at day 0, then 160 mg for 5 subsequent weekly doses)
Trial: 26882015
Drug: Pafuramidine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pafuramidine (100 mg orally twice a day for 10 days)
Trial: 26882015
Drug: Pentamidine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentamidine (4 mg/kg intramuscularly once daily for 7 days)
Trial: 24993817
Drug: Beclometasone/formoterol DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclometasone/formoterol DPI (children: 200 μg/24 μg, adolescents/adults: 400 μg/24 μg)
Trial: 24993817
Drug: Beclometasone/formoterol DPI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclometasone/formoterol DPI (adolescents/adults: 400 μg/24 μg)
Trial: 24993817
Drug: Normalization for
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normalization for BDP/formoterol dose
Trial: 21737312
Drug: Individualized intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized intervention to foster optimal antiretroviral treatment-taking behavior
Trial: 19568773
Drug: Aprepitant triple-therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant triple-therapy regimen (aprepitant, ondansetron, and dexamethasone)
Trial: 12578455
Drug: Fluorouracil (0.5‐mg/mL)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil (0.5‐mg/mL) applied to the rhinostomy site for 5 minutes during surgery
Trial: 12578455
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (isotonic sodium chloride solution) applied to the rhinostomy site for 5 minutes during surgery
Trial: 8639069
Drug: Subcutaneous dihydroergotamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous dihydroergotamine mesylate (1 mg)
Trial: 8639069
Drug: Subcutaneous sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subcutaneous sumatriptan succinate (6 mg)
Trial: 2062512
Drug: Early photocoagulation
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early photocoagulation (scatter and focal treatment)
Trial: 6852359
Drug: CDCA (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDCA (750 mg/day in three divided doses at meals)
Trial: 22269820
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cisatracurium (0.78 ± 0.15 μg.kg(‐1).min(‐1))
Trial: 22269820
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus injection of cisatracurium (1.09 ± 0.33 μg.kg(‐1).min(‐1))
Trial: 22269820
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of cisatracurium
Trial: 22269820
Drug: Intermittent bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent bolus injection of cisatracurium
Trial: 20578382
Drug: Single usage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single usage of acupoints of Shaoyang meridian (Fengchi (GB 20), Yifeng (TE 17), Wangu (GB 12) at the affected side) from the 3rd day to the 14th day, followed by routine acupoints (Hegu (LI 4) on both sides, Fengchi (GB 20), Quchi (LI 11), Yangbai (GB 14) at the affected side) after the 15th day, along with oral Prednisone.
Trial: 20578382
Drug: Routine acupoints
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine acupoints (same as the routine ones in the observation group) from the 3rd day, along with oral Prednisone.
Trial: 8529329
Drug: Intravenous EXP3174
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous EXP3174
Trial: 8529329
Drug: Oral EXP3174
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral EXP3174
Trial: 6305113
Drug: Preoperative irradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative irradiation with a total dose of 25.5 Gy in fractions of 5.1 Gy daily for 5 days
Trial: 27822727
Drug: Handcrafted vacuum‐assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Handcrafted vacuum‐assisted therapy (changed every 72 hours)
Trial: 27822727
Drug: Traditional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional treatment (debridement and cure with soap every 24 hours)
Trial: 23932021
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBOT) - 28 sessions at a partial pressure of oxygen of 240 kPa for 90 min
Trial: 21748755
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 25 mg of lenalidomide
Trial: 17606973
Drug: Ixabepilone 32
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 32 mg/m² 3-hour infusion (arm A)
Trial: 17606973
Drug: Ixabepilone 6
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ixabepilone 6 mg/m² 1-hour infusion daily for 5 consecutive days (arm B)
Trial: 16939989
Drug: Inhaled corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid add-on
Trial: 10821130
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor plus amlodipine (group II, n=13)
Trial: 10821130
Drug: ACE inhibitor
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitor alone (group I, n=17)
Trial: 2004543
Drug: Cefetamet pivoxil
RxNorm normalized name: Cefetamet pivoxil
DrugBank: Cefetamet pivoxil (DB18915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefetamet pivoxil 2000 mg daily for 10 days
Trial: 29164599
Drug: JWH‐018 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JWH‐018 2 mg
Trial: 29164599
Drug: JWH‐018 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JWH‐018 3 mg
Trial: 26136534
Drug: 30 g
RxNorm normalized name: Lancet Unilet 30 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 g whey protein (PRO) postexercise
Trial: 23032867
Drug: S‐ICD (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S‐ICD (subcutaneous implantable cardioverter-defibrillator)
Trial: 6688025
Drug: Atracurium 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.8 mg kg‐1
Trial: 30914216
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplement use
Trial: 15332578
Drug: Aspirin (250‐500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (250‐500 mg) + Clopidogrel (300 mg prehospital, then 75 mg/day after TLT)
Trial: 15332578
Drug: Aspirin (250‐500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (250‐500 mg)
Trial: 10691156
Drug: Universal screening
RxNorm normalized name: STATLOCK UNIVERSAL PLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Universal screening (50-g glucose challenge test followed by 3-h 100-g OGTT if plasma glucose at 1 h was >= 7.8 mmol/l)
Trial: 10691156
Drug: Risk factor-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risk factor-based screening (3-h 100-g OGTT at 32 weeks if any risk factor for GDM was present)
Trial: 30240907
Drug: Double contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double contrast injection in conjunctival lymphatics
Trial: 29202568
Drug: Hybrid hyaluronic
RxNorm normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hybrid hyaluronic acid (two intrarticular injections)
Trial: 29202568
Drug: High molecular
RxNorm normalized name: dextran, high molecular weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High molecular weight hyaluronic acid (two intrarticular injections)
Trial: 26518870
Drug: HOCO-DHA (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOCO-DHA (50 g/day) in muffins and cookies
Trial: 26518870
Drug: Barley flour
RxNorm normalized name: Barley malt flour
DrugBank: Barley malt (DB10980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barley flour (4.36 g/day of β-glucan) and control oil (50 g/day)
Trial: 26518870
Drug: Barley flour
RxNorm normalized name: Barley malt flour
DrugBank: Barley malt (DB10980)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Barley flour (4.36 g/day of β-glucan) and HOCO-DHA (50 g/day; DHA dosage 3 g/day)
Trial: 26518870
Drug: All-purpose flour
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-purpose flour and control oil (50 g/day)
Trial: 19748675
Drug: VPDT +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPDT + ITA (4 mg ITA injection)
Trial: 19748675
Drug: VPDT alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VPDT alone (sham injection)
Trial: 15139789
Drug: Intravenous palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous palonosetron 0.25 mg
Trial: 15139789
Drug: Intravenous palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous palonosetron 0.75 mg
Trial: 15139789
Drug: Intravenous palonosetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous palonosetron (0.25 or 0.75 mg)
Trial: 15139789
Drug: Intravenous dolasetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dolasetron 100 mg
Trial: 15139789
Drug: Intravenous dolasetron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous dolasetron
Trial: 11489748
Drug: Low-dose 13-cis-retinoic
RxNorm normalized name: 13-cis-retinoic acid
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose 13-cis-retinoic acid
Trial: 11489748
Drug: Oral cavity
RxNorm normalized name: INVEST ANTI-NEOPLASTIC DRUGS LIP,ORAL CAVITY AND PHARYNX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cavity site
Trial: 2292283
Drug: Aspirin 1.2
RxNorm normalized name: Aspirin 1.2 GM Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 1.2 g single dose
Trial: 2292283
Drug: Flurbiprofen 50
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50 mg t.d.s. for three days
Trial: 31550958
Drug: Compound glycyrrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound glycyrrhizin combined with fractional CO2 laser and triamcinolone acetonide solution
Trial: 31550958
Drug: Fractional CO2
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional CO2 laser and triamcinolone acetonide solution (Control)
Trial: 28847206
Drug: Anacetrapib 100
RxNorm normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib 100 mg once daily
Trial: 21332817
Drug: Tamsulosin 0.4
RxNorm normalized name: tamsulosin 0.4 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.4 mg per os daily (n = 33)
Trial: 19874160
Drug: Post-treatment social
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment social support
Trial: 16696911
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (regular therapy)
Trial: 14566102
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of prednisolone
Trial: 14566102
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg of prednisolone
Trial: 10660503
Drug: Cefpirome 1
RxNorm normalized name: cefpirome 100 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 1 g
Trial: 10660503
Drug: Cefpirome 2
RxNorm normalized name: Cefpirome
DrugBank: Cefpirome (DB13682)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome 2 g
Trial: 6142467
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg zopiclone
Trial: 2433653
Drug: Bleomycin (BLM)
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bleomycin (BLM) given perioperatively and 3 and 6 months postoperatively at a dosage of 150 mg per course (total: 450 mg)
Trial: 20467011
Drug: L-carnitine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (2 g twice daily) with hypocaloric diet
Trial: 18192785
Drug: Valaciclovir 500
RxNorm normalized name: valacyclovir 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir 500 mg once daily